Fox Rothschild Represents U.S. Management of Pioneering Technology Firm Serving Life Sciences Industry in Company SaleDecember 19, 2016 – Press Releases
Fox Rothschild LLP corporate and tax attorneys represented the U.S. management team of Phlexglobal, Ltd. in its majority shareholder acquisition by Vitruvian, an independent private equity firm that specializes in middle-market investments.
Phlexglobal is a world-renowned leader in the provision of electronic Trial Master File (eTMF) systems and services to the life science industry.
Fox attorneys Michael S. Harrington, Terrence M. Kerwin, Michael S. Bookbinder and Ethan Zook, represented Phlexglobal’s U.S. management team members in connection with their employment and equity arrangements with Vitruvian.
Phlexglobal CEO Rick Riegel said: “The guidance and direction we received from Michael and his team at Fox was invaluable. They combine high-level expertise and experience with a practical business sense. They worked diligently alongside us to close this important transaction. I have no doubt that we will be working with them again in future as we move forward with our new partner.”
As a result of the transaction, Vitruvian will become the majority shareholder of Phlexglobal, and Bridgepoint Development Capitol, the previous majority shareholder, will exit the company. The financial terms of the deal were not disclosed.
“Fox was pleased to advise Phlexglobal’s U.S. management team through this transaction, which will enhance their platform and grow their market leadership,” said Harrington.
Attorneys in Fox’s Corporate Department and Tax Department advise companies at all stages of growth and work to navigate the full range of business challenges they encounter – including corporate formation, management, growth, acquisitions and transfers – throughout the corporate life cycle.